- Latest available (Revised)
- Point in Time (31/12/2020)
- Original (As adopted by EU)
Commission Implementing Decision (EU) 2018/945 of 22 June 2018 on the communicable diseases and related special health issues to be covered by epidemiological surveillance as well as relevant case definitions (Text with EEA relevance)
When the UK left the EU, legislation.gov.uk published EU legislation that had been published by the EU up to IP completion day (31 December 2020 11.00 p.m.). On legislation.gov.uk, these items of legislation are kept up-to-date with any amendments made by the UK since then.
Legislation.gov.uk publishes the UK version. EUR-Lex publishes the EU version. The EU Exit Web Archive holds a snapshot of EUR-Lex’s version from IP completion day (31 December 2020 11.00 p.m.).
Point in time view as at 31/12/2020.
There are currently no known outstanding effects for the Commission Implementing Decision (EU) 2018/945, Division 2..
Revised legislation carried on this site may not be fully up to date. At the current time any known changes or effects made by subsequent legislation have been applied to the text of the legislation you are viewing by the editorial team. Please see ‘Frequently Asked Questions’ for details regarding the timescales for which new effects are identified and recorded on this site.
:
acute flaccid paralysis
:
acquired immune deficiency syndrome
:
antimicrobial resistance
:
hepatitis B core antibody
:
hepatitis C virus specific antibody
:
acute respiratory infection
:
broncho-alveolar lavage
:
Bacille de Calmette et Guérin
:
bone and joint infection
:
osteomyelitis
:
disc space infection
:
joint or bursa infection
:
botulinum neurotoxin
:
bloodstream infection
:
catheter-related — central venous catheter
:
Clostridium difficile associated diarrhoea
:
colony-forming unit
:
Creutzfeldt-Jakob disease
:
cytomegalovirus
:
EU Community Network of Reference Laboratories for human influenza
:
central nervous system
:
central nervous system infection — intracranial infection
:
central nervous system infection — meningitis or ventriculitis
:
central nervous system infection — spinal abscess without meningitis
:
catheter-related — peripheral venous catheter
:
catheter-related infection
:
Congenital rubella syndrome
:
capillary refilling time
:
Cerebrospinal fluid
:
computed tomography scan
:
cardiovascular system infection
:
cardiovascular system infection — myocarditis or pericarditis
:
cardiovascular system infection — endocarditis
:
cardiovascular system infection — mediastinitis
:
cardiovascular system infection — arterial or venous infection
:
direct fluorescent antibody
:
direct fluorescent antibody test for Treponema pallidum
:
deoxyribonucleic acid
:
distal protected aspirate
:
European Antimicrobial Resistance Surveillance Network
:
European Centre for Disease Prevention and Control
:
epidemiological cut-off values
:
electroencephalography
:
eye, ear, nose, throat, or mouth infection
:
eye, ear, nose, throat, or mouth infection — conjunctivitis
:
eye, ear, nose, throat, or mouth infection — ear mastoid
:
eye, ear, nose, throat, or mouth infection — eye, other than conjunctivitis
:
eye, ear, nose, throat, or mouth infection — oral cavity (mouth, tongue, or gums)
:
eye, ear, nose, throat, or mouth infection — sinusitis
:
eye, ear, nose, throat, or mouth infection — upper respiratory tract, pharyngitis, laryngitis, epiglottitis
:
European Federation of Neurological Societies
:
enzyme immunoassay
:
enzyme-linked immunosorbent assay
:
electron microscopy
:
European Committee on Antimicrobial Susceptibility Testing
:
fluorescent antibody to membrane antigen
:
fluorescent treponemal antibody absorption
:
fever of unknown origin
:
gastrointestinal system infection
:
gastrointestinal system infection — Clostridium difficile infection
:
gastrointestinal system infection — gastroenteritis (excl. CDI)
:
gastrointestinal system infection — gastrointestinal tract (esophagus, stomach, small and large bowel, and rectum) excluding gastroenteritis and appendicitis
:
gastrointestinal system infection — hepatitis
:
gastrointestinal system infection — intraabdominal, not specified elsewhere including gallbladder, bile ducts, liver (excluding viral hepatitis), spleen, pancreas, peritoneum, subphrenic or subdiaphragmatic space, or other intraabdominal tissue or area not specified elsewhere
:
healthcare-associated infections
:
hepatitis B e antigen
:
hepatitis B surface antigen
:
hepatitis B nucleic acid
:
hepatitis C virus core antigen
:
hepatitis C virus nucleic acid
:
human immunodeficiency virus
:
haemolytic-uraemic syndrome
:
intubation-associated pneumonia
:
indirect fluorescent antibody
:
immunoglobulin G
:
immunoglobulin M
:
influenza-like illness
:
lymphogranuloma (venereum)
:
lipopolysaccharides
:
lower respiratory tract infection, other than pneumonia
:
lower respiratory tract infection — bronchitis, tracheobronchitis, bronchiolitis, tracheitis, without evidence of pneumonia
:
Tick-borne encephalitis
The Whole Decision you have selected contains over 200 provisions and might take some time to download. You may also experience some issues with your browser, such as an alert box that a script is taking a long time to run.
Would you like to continue?
The Schedules you have selected contains over 200 provisions and might take some time to download. You may also experience some issues with your browser, such as an alert box that a script is taking a long time to run.
Would you like to continue?
Latest Available (revised):The latest available updated version of the legislation incorporating changes made by subsequent legislation and applied by our editorial team. Changes we have not yet applied to the text, can be found in the ‘Changes to Legislation’ area.
Original (As adopted by EU): The original version of the legislation as it stood when it was first adopted in the EU. No changes have been applied to the text.
Point in Time: This becomes available after navigating to view revised legislation as it stood at a certain point in time via Advanced Features > Show Timeline of Changes or via a point in time advanced search.
Geographical Extent: Indicates the geographical area that this provision applies to. For further information see ‘Frequently Asked Questions’.
Show Timeline of Changes: See how this legislation has or could change over time. Turning this feature on will show extra navigation options to go to these specific points in time. Return to the latest available version by using the controls above in the What Version box.
Access essential accompanying documents and information for this legislation item from this tab. Dependent on the legislation item being viewed this may include:
This timeline shows the different versions taken from EUR-Lex before exit day and during the implementation period as well as any subsequent versions created after the implementation period as a result of changes made by UK legislation.
The dates for the EU versions are taken from the document dates on EUR-Lex and may not always coincide with when the changes came into force for the document.
For any versions created after the implementation period as a result of changes made by UK legislation the date will coincide with the earliest date on which the change (e.g an insertion, a repeal or a substitution) that was applied came into force. For further information see our guide to revised legislation on Understanding Legislation.
Use this menu to access essential accompanying documents and information for this legislation item. Dependent on the legislation item being viewed this may include:
Click 'View More' or select 'More Resources' tab for additional information including: